ADPT
ADPT
Positions held
Your positionsADPT isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Adaptive Biotechnologies (ADPT) Stock Sees Modest Fair Value Lift On MRD Optimism
2026-10-06 · Adaptive Biotechnologies Insider Sold Shares Worth $1,014,329, According to a Recent SEC Filing
2026-09-25 · Adaptive Biotechnologies (ADPT) Stock Could Be 26% Above Fair Value Despite Guideline Update
2026-09-25 · Adaptive Biotechnologies (ADPT) Jumped, So What Is Driving Attention Now?
2026-09-24 · NCCN’s Myeloma MRD Update Spotlighting clonoSEQ Could Be A Game Changer For Adaptive Biotechnologies (ADPT)
2026-09-23 · Adaptive Biotechnologies (ADPT): Can Blood Cancer Guidelines Boost Repeat Testing?
2026-09-21 · Adaptive Biotechnologies Insider Sold Shares Worth $3,238,004, According to a Recent SEC Filing
2026-09-01 · Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
2026-08-24 · What Is Really Moving Tempus AI Stock Right Now?
2026-08-21 · Adaptive Biotechnologies Stock Has Doubled in the Past Year. Here’s What Could Come Next.
Price (daily)
Full chart · RSI · MACD · patterns